Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UVa Scientists Hot on Trail of Therapies for Deadly Lung Failure

23.02.2006


Researchers at the University of Virginia Health System have identified a molecular target, or receptor, for potential drugs to treat acute respiratory distress syndrome (ARDS), a sudden and life-threatening failure of the lung. Interestingly, the receptor is in the same class that gives people their sense of sight, smell and taste (G-protein coupled receptors.)



In ARDS, patients cannot breathe on their own because fluid gets into the lungs. Essentially, the body’s immune system causes lung inflammation and accumulation of fluid in the air sacs, or alveoli, leading to low blood-oxygen levels. Up to 30 percent of patients in intensive care units can die from ARDS. There is no current therapy other than general life support and putting patients on a breathing machine. If they survive, many people face long-term lung problems. Common causes of ARDS are pneumonia, septic shock, trauma, or inhaling chemicals.

The receptor identified by UVa doctors is called CXCR2. It’s expressed on the endothelial cells that line the blood vessels of the lung and on inflammatory leukocytes. Using animal models, UVa doctors have found that CXCR2 attracts white blood cells called neutrophils into the lung, a key event in the early development of ARDS. CXCR2 has been characterized in the past, but the endothelial cell effects define a new role for this receptor in the body’s physiology.


“We can’t say yet that if you target this receptor you will stop ARDS,” said Klaus Ley, M.D., Ph.D., director of the cardiovascular research center at UVa. “But it is reasonable to be hopeful and to pursue this type of research that might one day translate into clinical application.” Ley is senior author on a paper describing the receptor CXCR2 in the Feb. 16, 2006 “Online First Articles” of The Journal of Clinical Investigation found on the web at www.jci.org.

Dr. Jörg Reutershan, M.D., an anesthesiologist from Germany doing research in Ley’s lab, discovered that CXCR2 expressed on endothelial cells is involved in acute respiratory syndrome. “Our finding is that expression of this receptor is in the lung itself,” Reutershan said. “Our hope is that drug companies might be able to target the lung with an aerosol, which would have the advantage of hitting receptor without compromising the entire immune system, which is always a problem. Aerosol treatment would be a great advantage.”

The paper is titled “Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the lung.” 10.1172/JCI27009

Bob Beard | EurekAlert!
Further information:
http://www.jci.org
http://www.virginia.edu

More articles from Life Sciences:

nachricht Topologische Quantenchemie
21.07.2017 | Max-Planck-Institut für Chemische Physik fester Stoffe

nachricht Topological Quantum Chemistry
21.07.2017 | Max-Planck-Institut für Chemische Physik fester Stoffe

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA looks to solar eclipse to help understand Earth's energy system

21.07.2017 | Earth Sciences

Stanford researchers develop a new type of soft, growing robot

21.07.2017 | Power and Electrical Engineering

Vortex photons from electrons in circular motion

21.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>